Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sita-Hospital: Sitagliptin for Inpatient T2D
NCT01845831Phase 4Completed
- Sponsor
- Emory University
- Start
- Aug 2013
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sitagliptin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Emory University. Primary endpoints: Mean Blood Glucose Concentration After First Day of Treatment up to 10 Days and Change in HbA1C at Month 6. Started Aug 2013; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01845831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01845831.